1795 — Lotus Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual income statement for Lotus Pharmaceutical Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	10,729	12,649	14,633	16,958	18,584
Cost of Revenue
Gross Profit	4,597	5,640	7,806	9,384	10,924
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	9,154	10,397	10,538	12,159	12,565
Operating Profit	1,575	2,252	4,095	4,799	6,019
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,304	1,870	3,940	5,103	6,360
Provision for Income Taxes
Net Income After Taxes	1,030	1,403	3,021	4,106	5,066
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,027	1,403	3,021	4,106	5,066
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	1,027	1,403	3,021	4,106	5,066
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	4.77	6.29	12	16.6	19.7
Dividends per Share